The vector of anti-HBc18-27 T cell receptor (TCR) is constructed for the engineering of T cell to target HBV HBc18-27. The T cells are genetically modified through transduction with a lentiviral vector expressing HBc18-27-specific T cell receptor. And the vector product was designed for the treatment of HBV infection.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-TCR-C181||Lenti-HBc18-27 T cell receptor (C183) Viral Particle|
|VP-TCR-C182||Lenti-HBV T cell receptor (Cysteine-modiﬁed) Viral Particle|
|TCR-L042Z||Human anti-HBV (SIVSPFIPLL) T cell receptor (Cysteine-modiﬁed), pCDTCR1|
|TCR-L040Z||Human anti-HBV (FLGPLLVLQA) T cell receptor (Cysteine-modiﬁed), pCDTCR1|
|TCR-L041||Human anti-HBV (FLGPLLVLQA) T Cell Receptor, pMP71|
|TCR-L039Z||Human anti-HBV (FLPSDFFPSV) T cell receptor, pCDTCR1|
|TCR-L043Z||Human anti-HBV (FLLTRILTI) T cell receptor (Cysteine-modiﬁed), pCDTCR1|
|VP-TCR-C183||Lenti-HBV (FLPSDFFPSV) T cell receptor (Cysteine-modiﬁed) Viral Particle|
|TCR-L045||Human anti-HBV (FLPSDFFPSV) T Cell Receptor, pMP71|
|VP-TCR-C184||Lenti-HBV (SIVSPFIPLL) T cell receptor (Cysteine-modiﬁed) Viral Particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved